BioSpace News Archive

For several decades, veterinary vaccines have played a key role in improving food security and as a result, human health.

The increasing cases of kidney, liver, and heart diseases are likely to aid in expansion of the global alagille syndrome treatment market.

The Nordic regulatory affairs market is likely to be driven by a changing regulatory environment, rising demand for quicker clearance processes, and competitive and economic pressures.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical data from the ongoing Phase 1/2 trial evaluating darovasertib monotherapy and binimetinib combination therapy in patients with solid tumors, including Metastatic Uveal Melanoma and Skin Melanoma.

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first batch of patients enrolment and successfully dosed in China.

UCB reinforces commitment to delivering increased patient value by presenting latest research findings in epilepsy, myasthenia gravis, and Parkinson’s disease

On April 14, 2021 , GX Acquisition Corp. (“GX”) (NASDAQ: “GXGX”), provided information regarding a proposal to amend GX’s amended and restated certificate of incorporation (the “Charter”) to extend the date by which GX has to complete its initial business combination (the “Extension”) from May 23, 2021 to July 31, 2021 . The Charte

Labcorp, a leading global life sciences company, announced that its Annual Meeting of Shareholders will be webcast live beginning May 12, at 9:00 a.m. ET via the company website at www.Labcorp.com.

New findings from MS PATHS show that treatment with TYSABRI ® (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus ® (ocrelizumab) Real-world data from VUMERITY ® (diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab

Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions Ublituximab was generally well tolerated, with no unexpected safety signals BLA submission targeted in Q3 2021 Webcast to be held today, Friday, April 16, 2021 at 8:30 AM ET